INM Valuation

InMed Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

2.300

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

INM Relative Valuation

INM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INM is overvalued; if below, it's undervalued.

Historical Valuation

InMed Pharmaceuticals Inc (INM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.42 is considered Fairly compared with the five-year average of -1.01. The fair price of InMed Pharmaceuticals Inc (INM) is between 1.54 to 3.11 according to relative valuation methord.

Relative Value

Fair Zone

1.54-3.11

Current Price：2.30

Fair

-0.02

Trailing

Forward

0.00

EV/EBITDA

InMed Pharmaceuticals Inc. (INM) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.43. The thresholds are as follows: Strongly Undervalued below -2.16, Undervalued between -2.16 and -1.29, Fairly Valued between 0.44 and -1.29, Overvalued between 0.44 and 1.31, and Strongly Overvalued above 1.31. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.10

EV/EBIT

InMed Pharmaceuticals Inc. (INM) has a current EV/EBIT of 0.10. The 5-year average EV/EBIT is -0.41. The thresholds are as follows: Strongly Undervalued below -2.49, Undervalued between -2.49 and -1.45, Fairly Valued between 0.62 and -1.45, Overvalued between 0.62 and 1.66, and Strongly Overvalued above 1.66. The current Forward EV/EBIT of 0.10 falls within the Historic Trend Line -Fairly Valued range.

0.42

InMed Pharmaceuticals Inc. (INM) has a current PS of 0.42. The 5-year average PS is 2.55. The thresholds are as follows: Strongly Undervalued below -7.93, Undervalued between -7.93 and -2.69, Fairly Valued between 7.79 and -2.69, Overvalued between 7.79 and 13.03, and Strongly Overvalued above 13.03. The current Forward PS of 0.42 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

InMed Pharmaceuticals Inc. (INM) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.38. The thresholds are as follows: Strongly Undervalued below -1.73, Undervalued between -1.73 and -1.05, Fairly Valued between 0.30 and -1.05, Overvalued between 0.30 and 0.97, and Strongly Overvalued above 0.97. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.31

P/FCF

InMed Pharmaceuticals Inc. (INM) has a current P/FCF of 0.31. The 5-year average P/FCF is -0.15. The thresholds are as follows: Strongly Undervalued below -1.39, Undervalued between -1.39 and -0.77, Fairly Valued between 0.47 and -0.77, Overvalued between 0.47 and 1.10, and Strongly Overvalued above 1.10. The current Forward P/FCF of 0.31 falls within the Historic Trend Line -Fairly Valued range.

InMed Pharmaceuticals Inc (INM) has a current Price-to-Book (P/B) ratio of 0.40. Compared to its 3-year average P/B ratio of 0.29 , the current P/B ratio is approximately 39.40% higher. Relative to its 5-year average P/B ratio of 1.11, the current P/B ratio is about -64.14% higher. InMed Pharmaceuticals Inc (INM) has a Forward Free Cash Flow (FCF) yield of approximately -250.57%. Compared to its 3-year average FCF yield of -306.39%, the current FCF yield is approximately -18.22% lower. Relative to its 5-year average FCF yield of -206.71% , the current FCF yield is about 21.22% lower.

0.40

P/B

Median3y

0.29

Median5y

1.11

-250.57

FCF Yield

Median3y

-306.39

Median5y

-206.71

Competitors Valuation Multiple

The average P/S ratio for INM's competitors is 0.07, providing a benchmark for relative valuation. InMed Pharmaceuticals Inc Corp (INM) exhibits a P/S ratio of 0.42, which is 500.00% above the industry average. Given its robust revenue growth of 7.59%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

INM.O

InMed Pharmaceuticals Inc

China Pharma Holdings Inc

Performance Decomposition

Market capitalization of INM decreased by 67.61% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -146.93 to -168.12.

The secondary factor is the Revenue Growth, contributed 7.59%to the performance.

Overall, the performance of INM in the past 1 year is driven by Margin Expansion. Which is more sustainable.

7.59%

1.17M → 1.26M

Revenue Growth

14.42%

-146.93 → -168.12

Margin Expansion

-89.62%

-1.94 → -0.20

P/E Change

-67.61%